| Literature DB >> 28969701 |
Hidetsugu Maekawa1, Yoshiteru Tada2, Kenji Yagi2, Takeshi Miyamoto2, Keiko T Kitazato2, Masaaki Korai2, Junichiro Satomi2, Tomoki Hashimoto3, Shinji Nagahiro2.
Abstract
BACKGROUND: Estrogen deficiency is thought to be responsible for the higher frequency of aneurysmal subarachnoid hemorrhage in post- than premenopausal women. Estrogen replacement therapy appears to reduce this risk but is associated with significant side effects. We tested our hypothesis that bazedoxifene, a clinically used selective estrogen receptor (ER) modulator with fewer estrogenic side effects, reduces cerebral aneurysm rupture in a new model of ovariectomized rats.Entities:
Keywords: Estrogen; Estrogen receptor; Intracranial aneurysm; Selective estrogen receptor modulator; Subarachnoid hemorrhage
Mesh:
Substances:
Year: 2017 PMID: 28969701 PMCID: PMC5625708 DOI: 10.1186/s12974-017-0966-7
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Fig. 1a Incidence of aneurysm rupture within 12 weeks after aneurysm induction (*p < 0.05, Fisher’s exact test). b Sequential changes in the systolic blood pressure (*p < 0.05 vs sham, Scheffe’s test). c The body weight at 12 weeks after aneurysm induction (*p < 0.05, Scheffe’s test). Data are the mean ± SD. n = 23 – 27 per group
Fig. 2a mRNA level of estrogen receptor (ER)α and ERβ at the left posterior cerebral artery. The level was determined by quantitative real time-PCR and normalized by the glyceraldehyde 3-phophate dehydrogenase (GAPDH) mRNA level. n = 7 per group, *p < 0.05 (Scheffe’s test). Data are the mean ± SD. b Immunohistochemical staining for ERα and ERβ in the left posterior cerebral artery
Fig. 3mRNA level of (a) interleukin (IL)-1β, (b) IL-6, (c) tumor necrosis factor (TNF)-α in the left posterior cerebral artery. The levels were determined by quantitative real time-PCR and normalized by the glyceraldehyde 3-phophate dehydrogenase (GAPDH) mRNA level. *p < 0.05 (Scheffe’s test). Data are the mean ± SD. n = 7 per group
Fig. 4mRNA level of (a) matrix metalloproteinase (MMP)-9 and (b) tissue inhibitor of metalloproteinase (TIMP)-2 in the left posterior cerebral artery. The levels were determined by quantitative real time-PCR and normalized by the glyceraldehyde 3-phophate dehydrogenase (GAPDH) mRNA level. c Ratio of the MMP-9/TIMP-2 mRNA level. *p < 0.05 (Scheffe’s test). Data represent the mean ± SD. n = 7 per group